Are effects of MTHFR (C677T) genotype on BMD confined to women with low folate and riboflavin intake? Analysis of food records from the Danish osteoporosis prevention study.
We have previously found BMD and fracture risk to be significantly associated with the MTHFR (C677T) polymorphism in healthy postmenopausal women in the first years after menopause. Since then, other cohort studies have suggested that sufficient intake of riboflavin and/or folate may have the potential to prevent development of low BMD in women with the TT genotype. This could to some extent explain why this polymorphism is associated with low BMD or fracture in some study populations and not in others. It would also indicate that fractures associated with the TT genotype could be preventable by vitamin B supplementation. We have, therefore, reviewed baseline food record data from our original study to determine if BMD and fracture associations with the MTHFR genotype depended on the intake of folate, riboflavin, or other members of the vitamin B complex, associated with homocysteine metabolism. We analyzed genotype, BMD, and dietary records from 1700 healthy postmenopausal women who participated in the DOPS study. For the assessment of fracture risk, we used longitudinal observations from 854 women in the control group who remained compliant with their initial allocation of no treatment. Riboflavin intake was significantly correlated with femoral neck (FN) BMD in women with the TT genotype (r = 0.24, P < 0.01). FN and lumbar spine (LS) BMD were only associated with the MTHFR genotype in the lowest quartile of riboflavin intake. At the FN, similar threshold effects were shown for folate, vitamin B12, and vitamin B6. Among these vitamin B complex members, stepwise regression analysis identified riboflavin as the only significant predictor of FN BMD in the TT genotype. In conclusion, we confirm reports that BMD in the MTHFR TT genotype is only significantly reduced in the lowest quartile of riboflavin, B12, B6, and folate intake, at least at the time of menopause. Vitamin B supplementation would only be expected to benefit BMD in about 2% of the population, i.e., those with the TT genotype and low vitamin B intake.
Abrahamsen
Bo
B
Department of Endocrinology, Odense University Hospital, DK-5000 Odense C, Denmark. B.abrahamsen@dadlnet.dk
Madsen
Jonna Skov
JS
Tofteng
Charlotte Landbo
CL
Stilgren
Lis
L
Bladbjerg
Else Marie
EM
Kristensen
Søren Risom
SR
Brixen
Kim
K
Mosekilde
Leif
L
D015519:Bone Density / Q000235:genetics; D003596:Cytosine; D003718:Denmark; D015930:Diet Records; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage*; D005838:Genotype; D006801:Humans; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D008875:Middle Aged; D010024:Osteoporosis / Q000178:diet therapy / Q000235:genetics* / Q000517:prevention & control*; D015663:Osteoporosis, Postmenopausal / Q000178:diet therapy / Q000235:genetics / Q000517:prevention & control; D012256:Riboflavin / Q000008:administration & dosage*; D013941:Thymine
D003596:Cytosine; D005492:Folic Acid; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D013941:Thymine; D012256:Riboflavin